Retinoic acid receptor alpha · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Retinoic acid receptor alpha shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P10276. Start with myelodysplastic syndrome, then reuse UniProt P10276 as the stable protein anchor across project notes and exports.
Start with myelodysplastic syndrome, then reuse UniProt P10276 as the stable protein anchor across project notes and exports.
Retinoic acid receptor alpha shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with myelodysplastic syndrome because it currently carries late clinical support. Linked drugs include TAMIBAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRetinoic acid receptor alpha
Review this target as Retinoic acid receptor alpha, mapped to UniProt P10276. Sequence length is 462 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Retinoic acid receptor alpha as ChEMBL target CHEMBL2055, mapped to UniProt P10276. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Retinoic acid receptor alpha is the right protein anchor across sources, using UniProt P10276 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why myelodysplastic syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Retinoic acid receptor alpha |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P10276 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Retinoic acid receptor alpha |
| UniProt Accession | P10276 |
| Component Type | Protein |
| Sequence Length | 462 aa |
Retinoic acid receptor alpha
Review this target as Retinoic acid receptor alpha, mapped to UniProt P10276. Sequence length is 462 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Retinoic acid receptor alpha shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block.
Start review with myelodysplastic syndrome because it currently carries late clinical support. Linked drugs include TAMIBAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL38 | 10.0 | Ki | 0.1 | Approved |
| CHEMBL275311 | 9.74 | EC50 | 0.18 | Preclinical |
| CHEMBL69367 | 9.52 | EC50 | 0.3 | Preclinical |
| CHEMBL134375 | 9.35 | IC50 | 0.45 | Preclinical |
| CHEMBL451835 | 9.22 | EC50 | 0.6 | Preclinical |
| CHEMBL38 | 9.11 | IC50 | 0.78 | Approved |
| CHEMBL38 | 9.0 | EC50 | 1.01 | Approved |
| CHEMBL705 | 9.0 | EC50 | 1.0 | Approved |
| CHEMBL89241 | 8.96 | Ki | 1.1 | Preclinical |
| CHEMBL1235644 | 8.92 | EC50 | 1.2 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 111 | 129 | 6.9 |
| cell-based format | 102 | 129 | 6.8 |
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 54 | 16 | 7.3 |
| assay format | 30 | 26 | 7.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 17 | 6.9 |
| single protein format | 1 | 3 | 7.4 |